KMG Fiduciary Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15.9M | Sell |
63,078
-14,309
| -18% | -$3.08M | 1.47% | 19 |
|
|
2026
Q1 | $16.8M | Sell |
77,387
-388
| -0.5% | -$86.1K | 1.24% | 15 |
|
|
2025
Q4 | $17.8M | Buy |
77,775
+921
| +1% | +$210K | 1.26% | 13 |
|
|
2025
Q3 | $17.8M | Buy |
76,854
+1,940
| +3% | +$395K | 1.19% | 15 |
|
|
2025
Q2 | $13.9M | Buy |
74,914
+2,040
| +3% | +$379K | 1.03% | 19 |
|
|
2025
Q1 | $15.3M | Sell |
72,874
-10,403
| -12% | -$2.02M | 1.27% | 13 |
|
|
2024
Q4 | $14.8M | Buy |
83,277
+2,805
| +3% | +$516K | 1.23% | 13 |
|
|
2024
Q3 | $15.9M | Sell |
80,472
-5,585
| -6% | -$1.04M | 1.37% | 12 |
|
|
2024
Q2 | $14.8M | Buy |
86,057
+1,744
| +2% | +$289K | 1.45% | 13 |
|
|
2024
Q1 | $15.4M | Sell |
84,313
-808
| -0.9% | -$139K | 1.59% | 12 |
|
|
2023
Q4 | $13.2M | Buy |
85,121
+875
| +1% | +$128K | 1.54% | 13 |
|
|
2023
Q3 | $12.6M | Buy |
84,246
+2,057
| +3% | +$302K | 1.66% | 13 |
|
|
2023
Q2 | $11.1M | Buy |
82,189
+15,054
| +22% | +$2.21M | 1.43% | 13 |
|
|
2023
Q1 | $10.7M | Buy |
67,135
+1,880
| +3% | +$287K | 1.53% | 12 |
|
|
2022
Q4 | $10.5M | Buy |
65,255
+4,446
| +7% | +$682K | 1.73% | 8 |
|
|
2022
Q3 | $8.16M | Buy |
60,809
+8,967
| +17% | +$1.29M | 1.57% | 11 |
|
|
2022
Q2 | $7.94M | Sell |
51,842
-1,575
| -3% | -$241K | 1.48% | 13 |
|
|
2022
Q1 | $8.66M | Buy |
53,417
+716
| +1% | +$104K | 1.38% | 14 |
|
|
2021
Q4 | $7.14M | Buy |
52,701
+8,924
| +20% | +$1.05M | 1.1% | 21 |
|
|
2021
Q3 | $4.72M | Buy |
43,777
+17,180
| +65% | +$1.96M | 0.8% | 33 |
|
|
2021
Q2 | $3M | Buy |
26,597
+1,692
| +7% | +$191K | 0.53% | 48 |
|
|
2021
Q1 | $2.69M | Buy |
24,905
+3,827
| +18% | +$409K | 0.53% | 49 |
|
|
2020
Q4 | $2.25M | Buy |
21,078
+3,249
| +18% | +$312K | 0.47% | 50 |
|
|
2020
Q3 | $1.56M | Buy |
17,829
+698
| +4% | +$65.7K | 0.39% | 57 |
|
|
2020
Q2 | $1.68M | Sell |
17,131
-195
| -1% | -$17.2K | 0.47% | 54 |
|
|
2020
Q1 | $1.32M | Buy |
17,326
+4,453
| +35% | +$379K | 0.43% | 56 |
|
|
2019
Q4 | $1.14M | Buy |
12,873
+288
| +2% | +$23.9K | 0.35% | 52 |
|
|
2019
Q3 | $953K | Sell |
12,585
-6,254
| -33% | -$429K | 0.32% | 59 |
|
|
2019
Q2 | $1.37M | Buy |
18,839
+5,559
| +42% | +$437K | 0.5% | 41 |
|
|
2019
Q1 | $1.07M | Buy |
13,280
+6,151
| +86% | +$503K | 0.41% | 48 |
|
|
2018
Q4 | $657K | Buy |
+7,129
| New | +$627K | 0.3% | 61 |
|
Other funds holding ABBV
KMG Fiduciary Partners's ABBV Position: Q2 2026 in Review
KMG Fiduciary Partners reduced its AbbVie (ABBV) stake by 18% in Q2 2026, selling an estimated $3.08M and leaving 63,078 shares worth $15.9M. The position accounts for 1.47% of the portfolio, ranked #19.
KMG Fiduciary Partners first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. The position peaked at $17.8M in Q3 2025. 4,189 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- KMG Fiduciary Partners held 63,078 shares of AbbVie worth $15.9M as of Q2 2026.
- KMG Fiduciary Partners sold 14,309 AbbVie shares in Q2 2026, an estimated $3.08M.
- AbbVie made up 1.47% of KMG Fiduciary Partners's portfolio in Q2 2026, its #19 holding.
- KMG Fiduciary Partners first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- KMG Fiduciary Partners's AbbVie position peaked at $17.8M in Q3 2025.
- 4,189 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on KMG Fiduciary Partners's 13F filing for Q2 2026, filed 9 Jul 2026.